731 filings
Page 20 of 37
8-K
v9jxvuhfkt epwoje0
22 Apr 15
Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting
12:00am
CT ORDER
ffvmpqgw2k5h kyw
8 Apr 15
Confidential treatment order
12:00am
S-8
o5djdqck
5 Mar 15
Registration of securities for employees
12:00am
8-K
1l0chkkawk7ou2u
12 Feb 15
Acorda Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
12:00am
8-K
qoo5e1rea
2 Feb 15
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis
12:00am
8-K
ech6508lj0rut0
12 Jan 15
Acorda Provides Corporate Update at J.P. Morgan Healthcare Conference
12:00am
8-K/A
sdam0e5yzeonw7h
7 Jan 15
Report of Independent Registered Public Accounting Firm
12:00am
8-K
xq7yfn56jgddohunu
15 Dec 14
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
12:00am
8-K
teuvnivv ifw
10 Dec 14
Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease
12:00am
8-K
gjv2d4w1h3h3
30 Oct 14
Results of Operations and Financial Condition
12:00am
8-K
p3rpy
24 Oct 14
Acorda Therapeutics Completes Acquisition of Civitas Therapeutics
12:00am
8-K
qrz1tkb n3
26 Sep 14
Acorda Therapeutics to Acquire Civitas Therapeutics
12:00am
CT ORDER
r0i3xj
26 Aug 14
Confidential treatment order
12:00am
CT ORDER
7ws0l lupcv8dn496p
7 Aug 14
Confidential treatment order
12:00am
8-K
bqowf
31 Jul 14
Acorda Therapeutics Reports Second Quarter 2014 Financial Results
12:00am
8-K
102awbfb fgxx31kjy
9 Jul 14
Other Events
12:00am
8-K
rels z0ph
26 Jun 14
Other Events
12:00am